Trump seeking economic deal with China as fresh trade talks loom- WSJ
In a recent SEC filing, Health Catalyst , Inc. (NASDAQ:HCAT) disclosed that its Chief Operating Officer, Daniel LeSueur, sold 22,773 shares of the company's common stock. The transaction, which took place on December 4, 2024, was executed at an average price of $7.6952 per share, amounting to a total value of approximately $175,242. The stock, currently trading at $8.35, has shown resilience since the sale, with the company maintaining a market capitalization of roughly $507 million. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value assessment.
Following this sale, LeSueur retains ownership of 96,462 shares in Health Catalyst. The sale was conducted under a pre-established trading plan, as per Rule 10b5-1, which allows company insiders to set up a predetermined schedule for selling stocks to avoid potential conflicts of interest. While not currently profitable, InvestingPro data indicates analysts expect profitability this year, with 6 analysts recently revising earnings estimates upward. Discover more insights and 5 additional ProTips with an InvestingPro subscription.
In other recent news, Health Catalyst Inc. has experienced a series of significant developments. The company's third quarter financial results for 2024 showed a positive profit and loss execution, with a shift back towards software in its revenue mix. This positive financial performance led to revisions in the price targets by both Piper Sandler and Stephens. Piper Sandler raised its target from $11.00 to $12.00, maintaining an Overweight rating, while Stephens increased its target from $7.00 to $9.00, keeping an Equal Weight rating.
These revisions were influenced by Health Catalyst's robust growth outlook, including an expected year-over-year growth of approximately 50% in adjusted EBITDA for calendar year 2025, as indicated by the company's leadership. Piper Sandler's adjustment also considered the company's bookings mix, implementation timelines, segment margins trends, cross-selling initiatives, and plans for interest expense and upcoming convertible notes due in 2025.
Stephens, on the other hand, pointed out the importance of the fourth quarter's bookings outcomes, which could affect projections. Despite these developments, both firms are awaiting more clarity on Health Catalyst's growth for fiscal year 2025 before adopting a more constructive stance. These recent developments underscore the evolving financial landscape of Health Catalyst as it continues to navigate the dynamic healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.